Adding Brachytherapy After Chemoradiotherapy for Esophageal Cancer
Official title: To Observe the Local Tumor Recurrence Rate of Adding Intraluminal Brachytherapy With Balloon Applicator After Standard Definitive Concurrent Chemoradiotherapy (CCRT) on Local-regional Thoracic Esophageal Cancer Patients Who Refused Surgery
Run by Chang Gung Memorial Hospital · NCT05145647 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if adding a new type of targeted radiation therapy after chemotherapy and radiation can help people with esophageal cancer who aren't having surgery control their tumors better and live longer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 20 Years to 85 Years |
| Sex | All |
| Enrollment | 18 (estimated) |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Taoyuan City) |
| Trial ID | NCT05145647 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 20-85 with clinical stage I-III thoracic esophageal cancer who have completed CCRT and have resectable tumors but declined surgery.
✕Probably not a fit
Patients with advanced T4b tumors, significant esophageal stenosis, or those participating in other clinical trials may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effects of adding intraluminal brachytherapy using an innovative applicator after definitive concurrent chemoradiotherapy (CCRT) in patients with resectable esophageal cancer who have opted out of surgery. The primary goal is to observe changes in local tumor control rates, while secondary goals include assessing treatment-related toxicity, progression-free survival, and overall survival. The new brachytherapy applicator aims to enhance therapeutic efficacy by minimizing dose inhomogeneity in the esophageal wall, potentially reducing the risk of severe side effects associated with traditional methods.
Why it matters
Potential benefit: If successful, this approach could improve local tumor control and reduce complications for patients with esophageal cancer.
How similar studies have gone: While brachytherapy has been used in esophageal cancer treatment, the specific application of the innovative Braxx applicator represents a novel approach that has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age of 20-85 years, with ECOG performance 0-2 2. Thoracic esophageal cancer with clinical stage I-III and biopsy proof; patient with cervical esophageal cancer or stage IV thoracic esophageal cancer could be recruited in this trial according to Investigator's assessment. 3. Complete first course CCRT with minimum doses of 40 Gy to tumor and nodal area via external beam radiotherapy (EBRT). 4. Patient whose tumor is resectable but declined to receive surgery after first course CCRT. Exclusion Criteria: 1. T4b tumor status (tracheal / bronchial mucosa, aortic involvement, or fistula formation). 2. Stenosis of esophageal lumen that cannot be bypassed by the applicator. 3. The primary tumor length exceeds 20cm. 4. The patient is participating in other clinical trials.
Where it's running
-
Linkou Chang Gung Memorial Hospital
Taoyuan City, Taiwan Recruiting
Study contacts
- Principal investigator: Chen-Kan Tseng, MD — Chang Gung Memorial Hospital
- Study coordinator: Chen-Kan Tseng, MD
- Email: kantseng@adm.cgmh.org.tw
- Phone: +886-3-3281200
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PF-08098488 in adults with advanced solid tumors
This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.
-
Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer
This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.
-
MGC030 in adults with advanced solid tumors
This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
TS-104: a first-in-human, dose-escalation study for advanced solid tumors
This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.
-
First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors
This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.